Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2021
Price :
$35
*
At a glance
- Drugs ASP 3652 (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Acronyms AMARANTH
- Sponsors Astellas Pharma Europe Ltd
- 15 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Jun 2012 Planned end date changed from 1 Feb 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 08 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01613586).